GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (ASX:PYC) » Definitions » ROC (Joel Greenblatt) %

PYC Therapeutics (ASX:PYC) ROC (Joel Greenblatt) % : -2,077.82% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is PYC Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PYC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,077.82%.

The historical rank and industry rank for PYC Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:PYC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5441.78   Med: -1907.37   Max: -915.63
Current: -2535.15

During the past 13 years, PYC Therapeutics's highest ROC (Joel Greenblatt) % was -915.63%. The lowest was -5441.78%. And the median was -1907.37%.

ASX:PYC's ROC (Joel Greenblatt) % is ranked worse than
78.79% of 1410 companies
in the Biotechnology industry
Industry Median: -307.695 vs ASX:PYC: -2535.15

PYC Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 21.00% per year.


PYC Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for PYC Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics ROC (Joel Greenblatt) % Chart

PYC Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,204.57 -1,418.62 -915.63 -1,746.18 -2,908.75

PYC Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,064.43 -1,993.41 -910.71 -2,077.82 -2,639.82

Competitive Comparison of PYC Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, PYC Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's ROC (Joel Greenblatt) % falls into.



PYC Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.049000000000003) - (7.463 + 0 + 0.765)
=-8.179

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.672 + 0 + 0.314) - (7.409 + 0 + 0.898)
=0.679

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of PYC Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-30.44/( ( (1.043 + max(-8.179, 0)) + (1.208 + max(0.679, 0)) )/ 2 )
=-30.44/( ( 1.043 + 1.887 )/ 2 )
=-30.44/1.465
=-2,077.82 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PYC Therapeutics  (ASX:PYC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


PYC Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


PYC Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics Headlines

No Headlines